Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 14

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 14
---
 will not receive any proceeds from the resale of the Depositary                                                                           
 Shares to be offered by the Selling Securityholder. Additionally, we will not receive any proceeds from the issuance or sale of              
 the Commitment Shares if issued to the Selling Shareholder to release the Company of its liability to pay the Commitment Fee. We may receive 
 up to $35.0 million in gross proceeds from C/M in connection with the sale of our Depositary Shares under the Purchase Agreement. We intend  
 to use any net proceeds from any sales of Depositary Shares to C/M under the Equity Financing to fund our development programs, for working  
 capital and other general corporate purposes. Pending other uses, we intend to invest the net proceeds to us in short-term, interest-bearing 
 investments. We cannot predict whether the net proceeds invested will yield a favorable return. See “Use of Proceeds.”                       |

| Risk factors    |     | You should read the “Risk Factors” section starting                                                                                                                                          
 on page 10 of this prospectus for a discussion of factors to consider before deciding to invest in our securities.                                                                           |
| Dividend policy |     | We have never declared or paid any cash dividends to our shareholders, and we currently do not expect to declare or pay any cash dividends in the foreseeable future. See “Dividend Policy.” |
| Listing         |     | Our Depositary Shares are listed on the NASDAQ Capital Market under the symbol “BDRX.”                                                                                                       |

| 9 |

<div align='center'>RISK FACTORS</div>

Our business has significant risks. In addition to the other information included in this annual report, including the matters addressed in the section of the annual report entitled “Cautionary Note Regarding Forward-Looking Statements” and in our financial statements and the related notes, you should consider carefully the risks described below. The risks and uncertainties described below are not the only risks and uncertainties we may face. Additional risks and uncertainties not presently known to us, or that we currently consider immaterial could also negatively affect our business, financial condition, results of operations, prospects, profits and stock prices. If any of the risks described below actually occur, our business, financial condition, results of operations, prospects, profits and stock prices could be materially adversely affected.

The sale of a substantial amount of our Ordinary Shares (represented by Depositary Shares), including resale of the Ordinary Shares (represented by Depositary Shares) issuable upon the exercise of the warrants held by the selling shareholders in the public market could adversely affect the